
Sarah J Baracz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7151563/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behavioural Brain Research, 2012, 228, 185-193.	2.2	88
2	Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamineâ€seeking behaviour in rats. Addiction Biology, 2016, 21, 316-325.	2.6	69
3	Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. Journal of Psychopharmacology, 2018, 32, 1369-1378.	4.0	56
4	Adolescent preâ€ŧreatment with oxytocin protects against adult methamphetamineâ€seeking behavior in female rats. Addiction Biology, 2016, 21, 304-315.	2.6	43
5	The neurocircuitry involved in oxytocin modulation of methamphetamine addiction. Frontiers in Neuroendocrinology, 2016, 43, 1-18.	5.2	43
6	The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology, 2018, 133, 1-11.	4.1	37
7	The vagus nerve mediates the suppressing effects of peripherally administered oxytocin on methamphetamine self-administration and seeking in rats. Neuropsychopharmacology, 2021, 46, 297-304.	5.4	37
8	Oxytocin modulates dopamine-mediated reward in the rat subthalamic nucleus. Hormones and Behavior, 2013, 63, 370-375.	2.1	35
9	The impact of early life stress on the central oxytocin system and susceptibility for drug addiction: Applicability of oxytocin as a pharmacotherapy. Neuroscience and Biobehavioral Reviews, 2020, 110, 114-132.	6.1	34
10	The effect of chronic oxytocin treatment during abstinence from methamphetamine self-administration on incubation of craving, reinstatement, and anxiety. Neuropsychopharmacology, 2020, 45, 597-605.	5.4	31
11	The L-type calcium channel blocker, isradipine, attenuates cue-induced cocaine-seeking by enhancing dopaminergic activity in the ventral tegmental area to nucleus accumbens pathway. Neuropsychopharmacology, 2018, 43, 2361-2372.	5.4	24
12	Maternal separation changes maternal care, anxietyâ€like behaviour and expression of paraventricular oxytocin and corticotrophinâ€releasing factor immunoreactivity in lactating rats. Journal of Neuroendocrinology, 2020, 32, e12861.	2.6	21
13	Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. Brain Research Bulletin, 2016, 127, 208-218.	3.0	19
14	Oxytocin treatment in the prelimbic cortex reduces relapse to methamphetamine-seeking and is associated with reduced activity in the rostral nucleus accumbens core. Pharmacology Biochemistry and Behavior, 2019, 183, 64-71.	2.9	17
15	Sign tracking predicts cue-induced but not drug-primed reinstatement to methamphetamine seeking in rats: Effects of oxytocin treatment. Journal of Psychopharmacology, 2020, 34, 1271-1279.	4.0	16
16	Adolescent oxytocin administration reduces depression-like behaviour induced by early life stress in adult male and female rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110279.	4.8	9
17	Differential effects of GABAA receptor activation in the prelimbic and orbitofrontal cortices on anxiety. Psychopharmacology, 2020, 237, 3237-3247.	3.1	8
18	Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats. Neuropsychopharmacology, 2022, 47, 1561-1573.	5.4	5

SARAH J BARACZ

#	Article	IF	CITATIONS
19	A Piriform-Orbitofrontal Cortex Pathway Drives Relapse to Fentanyl-Seeking after Voluntary Abstinence. Journal of Neuroscience, 2020, 40, 8208-8210.	3.6	2
20	Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology, 2022, 239, 1593-1603.	3.1	2
21	The effect of adolescent social isolation on vulnerability for methamphetamine addiction behaviours in female rats. Psychopharmacology, 2022, 239, 1129-1141.	3.1	1
22	Opportunities for innovation and translation in behavioral neuroscience. Pharmacology Biochemistry and Behavior, 2020, 195, 172957.	2.9	0